Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-12

AUTHORS

Marjolijn van Keep, Kerry Gairy, Divyagiri Seshagiri, Pushpike Thilakarathne, Dawn Lee

ABSTRACT

BACKGROUND: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma. Bortezomib is the first product to be approved for the treatment of patients with previously untreated MCL, for whom haematopoietic stem cell transplantation is unsuitable, and is used in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP). The National Institute of Health and Care Excellence recently recommended the use of VR-CAP in the UK following a technology appraisal. We present the cost effectiveness analysis performed as part of that assessment: VR-CAP versus the current standard of care regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in a UK setting. METHODS: A lifetime economic model was developed with health states based upon line of treatment and progression status. Baseline patient characteristics, dosing, safety and efficacy were based on the LYM-3002 trial. As overall survival data were immature, survival was modelled by progression status, and post-progression survival was assumed equal across arms. Utilities were derived from LYM-3002 and literature, and standard UK cost sources were used. RESULTS: Treatment with VR-CAP compared to R-CHOP gave an incremental quality-adjusted life year (QALY) gain of 0.81 at an additional cost of £16,212, resulting in a base case incremental cost-effectiveness ratio of £20,043. Deterministic and probabilistic sensitivity analyses showed that treatment with VR-CAP was cost effective at conventional willingness-to-pay thresholds (£20,000-£30,000 per QALY). CONCLUSIONS: VR-CAP is a cost-effective option for previously untreated patients with MCL in the UK. More... »

PAGES

598

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-016-2633-2

DOI

http://dx.doi.org/10.1186/s12885-016-2633-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014933792

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27488675


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bortezomib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Mantle-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "BresMed, Arthur van Schendelstraat 650, 3511MJ, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Keep", 
        "givenName": "Marjolijn", 
        "id": "sg:person.01215062721.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215062721.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Janssen-Cilag, 50-100 Holmers Farm Way, HP12 4EG, High Wycombe, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gairy", 
        "givenName": "Kerry", 
        "id": "sg:person.0734435561.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734435561.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Janssen-Cilag, Johnson & Johnson Platz 1, 41470, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seshagiri", 
        "givenName": "Divyagiri", 
        "id": "sg:person.01035527511.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035527511.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Janssen-Cilag, Turnhoutseweg 30, B-2340, Beerse, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thilakarathne", 
        "givenName": "Pushpike", 
        "id": "sg:person.01344021601.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344021601.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BresMed", 
          "id": "https://www.grid.ac/institutes/grid.482857.4", 
          "name": [
            "BresMed, 84 Queen Street, S1 2DW, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Dawn", 
        "id": "sg:person.01165765467.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165765467.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/bjh.12046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001169896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-03-559930", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007936408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009556116", 
          "https://doi.org/10.1038/bjc.2015.94"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1412096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010737036"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2011.05.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011370408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.08.133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012126812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-003-0774-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014607777", 
          "https://doi.org/10.1007/s00277-003-0774-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2007-06-095331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016624678"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2014.08.568", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016881355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428194.2012.733882", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018029031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61763-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020265499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-05-521898", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022647132"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024326332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2016.04.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027619598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428194.2012.656628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030110268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2006.05970.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034825932"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2006.05970.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034825932"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037425350"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1200920", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039844684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.2005.00438.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047241465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.2005.00438.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047241465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.8435", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053491476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.20.5.1288", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064202851"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.55.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/107327481201900307", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078579904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/107327481201900307", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078579904"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-12", 
    "datePublishedReg": "2016-12-01", 
    "description": "BACKGROUND: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma. Bortezomib is the first product to be approved for the treatment of patients with previously untreated MCL, for whom haematopoietic stem cell transplantation is unsuitable, and is used in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP). The National Institute of Health and Care Excellence recently recommended the use of VR-CAP in the UK following a technology appraisal. We present the cost effectiveness analysis performed as part of that assessment: VR-CAP versus the current standard of care regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in a UK setting.\nMETHODS: A lifetime economic model was developed with health states based upon line of treatment and progression status. Baseline patient characteristics, dosing, safety and efficacy were based on the LYM-3002 trial. As overall survival data were immature, survival was modelled by progression status, and post-progression survival was assumed equal across arms. Utilities were derived from LYM-3002 and literature, and standard UK cost sources were used.\nRESULTS: Treatment with VR-CAP compared to R-CHOP gave an incremental quality-adjusted life year (QALY) gain of 0.81 at an additional cost of \u00a316,212, resulting in a base case incremental cost-effectiveness ratio of \u00a320,043. Deterministic and probabilistic sensitivity analyses showed that treatment with VR-CAP was cost effective at conventional willingness-to-pay thresholds (\u00a320,000-\u00a330,000 per QALY).\nCONCLUSIONS: VR-CAP is a cost-effective option for previously untreated patients with MCL in the UK.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-016-2633-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "name": "Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma", 
    "pagination": "598", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "47268790d2a5d88c60b150b1f4e735083642b844529aa1b0a513ac60901e62ab"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27488675"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-016-2633-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014933792"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-016-2633-2", 
      "https://app.dimensions.ai/details/publication/pub.1014933792"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87115_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-016-2633-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2633-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2633-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2633-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2633-2'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      21 PREDICATES      67 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-016-2633-2 schema:about N03c32561d47641aea2ee91631e3303e1
2 N2332ab1ad07d451a9c48ca050d46f1de
3 N3dc6a7d2c6b449808999b55c824fedd1
4 N40f2511511324c0581ca52a68bd0f04b
5 N56941875210f45859f90cc0a3c94fa58
6 N5b2d4dc950b34307a6e1cd61dc8c1405
7 N7a9c30792cfc4f20a397a698fa54d227
8 N7c2fe579861249c38ba6bcf9ec20aea6
9 Na904d980d2514dc485091e728f36ef02
10 Naf52abc8a5a8423a8f916ff658b0ac6a
11 Nd1cc7fdb68774c7a986e0b7689586177
12 Ne3aee5cd9eb246839c064699555c4d97
13 Ne7c99a290282429b85a3d6dd2589d824
14 Ne93b7ab5bdb445feb92ddc5f5c6ade6c
15 Nfdab5d43b8b144c5a7764acfa6899fc4
16 anzsrc-for:14
17 anzsrc-for:1402
18 schema:author Nbcc00e48835a4aabab22eb40d7d318bf
19 schema:citation sg:pub.10.1007/s00277-003-0774-2
20 sg:pub.10.1038/bjc.2015.94
21 https://doi.org/10.1016/j.critrevonc.2011.05.001
22 https://doi.org/10.1016/j.jval.2014.08.568
23 https://doi.org/10.1016/j.jval.2016.04.013
24 https://doi.org/10.1016/s0140-6736(12)61763-2
25 https://doi.org/10.1056/nejmoa1200920
26 https://doi.org/10.1056/nejmoa1412096
27 https://doi.org/10.1093/annonc/mds643
28 https://doi.org/10.1093/annonc/mdu264
29 https://doi.org/10.1111/bjh.12046
30 https://doi.org/10.1111/j.1365-2141.2006.05970.x
31 https://doi.org/10.1111/j.1600-0609.2005.00438.x
32 https://doi.org/10.1177/107327481201900307
33 https://doi.org/10.1182/blood-2007-06-095331
34 https://doi.org/10.1182/blood-2014-03-559930
35 https://doi.org/10.1182/blood-2014-05-521898
36 https://doi.org/10.1200/jco.20.5.1288
37 https://doi.org/10.1200/jco.2005.08.133
38 https://doi.org/10.1200/jco.2005.55.017
39 https://doi.org/10.1200/jco.2008.16.8435
40 https://doi.org/10.3109/10428194.2012.656628
41 https://doi.org/10.3109/10428194.2012.733882
42 schema:datePublished 2016-12
43 schema:datePublishedReg 2016-12-01
44 schema:description BACKGROUND: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma. Bortezomib is the first product to be approved for the treatment of patients with previously untreated MCL, for whom haematopoietic stem cell transplantation is unsuitable, and is used in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP). The National Institute of Health and Care Excellence recently recommended the use of VR-CAP in the UK following a technology appraisal. We present the cost effectiveness analysis performed as part of that assessment: VR-CAP versus the current standard of care regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in a UK setting. METHODS: A lifetime economic model was developed with health states based upon line of treatment and progression status. Baseline patient characteristics, dosing, safety and efficacy were based on the LYM-3002 trial. As overall survival data were immature, survival was modelled by progression status, and post-progression survival was assumed equal across arms. Utilities were derived from LYM-3002 and literature, and standard UK cost sources were used. RESULTS: Treatment with VR-CAP compared to R-CHOP gave an incremental quality-adjusted life year (QALY) gain of 0.81 at an additional cost of £16,212, resulting in a base case incremental cost-effectiveness ratio of £20,043. Deterministic and probabilistic sensitivity analyses showed that treatment with VR-CAP was cost effective at conventional willingness-to-pay thresholds (£20,000-£30,000 per QALY). CONCLUSIONS: VR-CAP is a cost-effective option for previously untreated patients with MCL in the UK.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree true
48 schema:isPartOf N3612cb73dd414f1588f096193f9dbabd
49 Nc94d331989c44f7dadc92231e24c7e59
50 sg:journal.1024632
51 schema:name Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
52 schema:pagination 598
53 schema:productId N3582158a063445ceb15e822146829e62
54 N487f681355fe405c9b73c4094470aa38
55 N5f7b89b425a14dfbae18707f7ca144a3
56 Nf7c44c2edcbb42ad9abc9b90d4092a56
57 Nfd89e6844d8a4a7e9e73577e51d4304f
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014933792
59 https://doi.org/10.1186/s12885-016-2633-2
60 schema:sdDatePublished 2019-04-11T12:26
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N3e638d57b3eb41ad87a4164df1274f8a
63 schema:url https://link.springer.com/10.1186%2Fs12885-016-2633-2
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N03c32561d47641aea2ee91631e3303e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Bortezomib
69 rdf:type schema:DefinedTerm
70 N2332ab1ad07d451a9c48ca050d46f1de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Humans
72 rdf:type schema:DefinedTerm
73 N3582158a063445ceb15e822146829e62 schema:name dimensions_id
74 schema:value pub.1014933792
75 rdf:type schema:PropertyValue
76 N3612cb73dd414f1588f096193f9dbabd schema:volumeNumber 16
77 rdf:type schema:PublicationVolume
78 N3dc6a7d2c6b449808999b55c824fedd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Quality-Adjusted Life Years
80 rdf:type schema:DefinedTerm
81 N3e638d57b3eb41ad87a4164df1274f8a schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 N40f2511511324c0581ca52a68bd0f04b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Antineoplastic Combined Chemotherapy Protocols
85 rdf:type schema:DefinedTerm
86 N450a581afd34411293fa7eac70947398 rdf:first sg:person.0734435561.80
87 rdf:rest N95aa660c3bc345b3acfa3677632f9931
88 N487f681355fe405c9b73c4094470aa38 schema:name doi
89 schema:value 10.1186/s12885-016-2633-2
90 rdf:type schema:PropertyValue
91 N4f358bb1c5674eca9a4c5f11bc65ea52 schema:name Janssen-Cilag, 50-100 Holmers Farm Way, HP12 4EG, High Wycombe, UK
92 rdf:type schema:Organization
93 N56941875210f45859f90cc0a3c94fa58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Vincristine
95 rdf:type schema:DefinedTerm
96 N588ceafe4659436e8b4b78a4689cf1e9 rdf:first sg:person.01344021601.48
97 rdf:rest Nbd6006c5c72742cc8ac6367b0fc4ff2b
98 N5b2d4dc950b34307a6e1cd61dc8c1405 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Cost-Benefit Analysis
100 rdf:type schema:DefinedTerm
101 N5f7b89b425a14dfbae18707f7ca144a3 schema:name nlm_unique_id
102 schema:value 100967800
103 rdf:type schema:PropertyValue
104 N7a9c30792cfc4f20a397a698fa54d227 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Cyclophosphamide
106 rdf:type schema:DefinedTerm
107 N7c2fe579861249c38ba6bcf9ec20aea6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Female
109 rdf:type schema:DefinedTerm
110 N95aa660c3bc345b3acfa3677632f9931 rdf:first sg:person.01035527511.06
111 rdf:rest N588ceafe4659436e8b4b78a4689cf1e9
112 Na904d980d2514dc485091e728f36ef02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name United Kingdom
114 rdf:type schema:DefinedTerm
115 Naf52abc8a5a8423a8f916ff658b0ac6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Prednisone
117 rdf:type schema:DefinedTerm
118 Nb90d6420ad974ddb8dc93c33e6b3bd95 schema:name Janssen-Cilag, Turnhoutseweg 30, B-2340, Beerse, Belgium
119 rdf:type schema:Organization
120 Nbcc00e48835a4aabab22eb40d7d318bf rdf:first sg:person.01215062721.00
121 rdf:rest N450a581afd34411293fa7eac70947398
122 Nbd6006c5c72742cc8ac6367b0fc4ff2b rdf:first sg:person.01165765467.03
123 rdf:rest rdf:nil
124 Nc94d331989c44f7dadc92231e24c7e59 schema:issueNumber 1
125 rdf:type schema:PublicationIssue
126 Nd1cc7fdb68774c7a986e0b7689586177 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Rituximab
128 rdf:type schema:DefinedTerm
129 Nde3905552ef5484d9b908873ea9dda6d schema:name BresMed, Arthur van Schendelstraat 650, 3511MJ, Utrecht, The Netherlands
130 rdf:type schema:Organization
131 Ne3aee5cd9eb246839c064699555c4d97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Kaplan-Meier Estimate
133 rdf:type schema:DefinedTerm
134 Ne7c99a290282429b85a3d6dd2589d824 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Doxorubicin
136 rdf:type schema:DefinedTerm
137 Ne93b7ab5bdb445feb92ddc5f5c6ade6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Lymphoma, Mantle-Cell
139 rdf:type schema:DefinedTerm
140 Nf7c44c2edcbb42ad9abc9b90d4092a56 schema:name readcube_id
141 schema:value 47268790d2a5d88c60b150b1f4e735083642b844529aa1b0a513ac60901e62ab
142 rdf:type schema:PropertyValue
143 Nfd89e6844d8a4a7e9e73577e51d4304f schema:name pubmed_id
144 schema:value 27488675
145 rdf:type schema:PropertyValue
146 Nfdab5d43b8b144c5a7764acfa6899fc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Male
148 rdf:type schema:DefinedTerm
149 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
150 schema:name Economics
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
153 schema:name Applied Economics
154 rdf:type schema:DefinedTerm
155 sg:journal.1024632 schema:issn 1471-2407
156 schema:name BMC Cancer
157 rdf:type schema:Periodical
158 sg:person.01035527511.06 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
159 schema:familyName Seshagiri
160 schema:givenName Divyagiri
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035527511.06
162 rdf:type schema:Person
163 sg:person.01165765467.03 schema:affiliation https://www.grid.ac/institutes/grid.482857.4
164 schema:familyName Lee
165 schema:givenName Dawn
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165765467.03
167 rdf:type schema:Person
168 sg:person.01215062721.00 schema:affiliation Nde3905552ef5484d9b908873ea9dda6d
169 schema:familyName van Keep
170 schema:givenName Marjolijn
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215062721.00
172 rdf:type schema:Person
173 sg:person.01344021601.48 schema:affiliation Nb90d6420ad974ddb8dc93c33e6b3bd95
174 schema:familyName Thilakarathne
175 schema:givenName Pushpike
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344021601.48
177 rdf:type schema:Person
178 sg:person.0734435561.80 schema:affiliation N4f358bb1c5674eca9a4c5f11bc65ea52
179 schema:familyName Gairy
180 schema:givenName Kerry
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734435561.80
182 rdf:type schema:Person
183 sg:pub.10.1007/s00277-003-0774-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014607777
184 https://doi.org/10.1007/s00277-003-0774-2
185 rdf:type schema:CreativeWork
186 sg:pub.10.1038/bjc.2015.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009556116
187 https://doi.org/10.1038/bjc.2015.94
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/j.critrevonc.2011.05.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011370408
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.jval.2014.08.568 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016881355
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/j.jval.2016.04.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027619598
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/s0140-6736(12)61763-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020265499
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejmoa1200920 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039844684
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1056/nejmoa1412096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010737036
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1093/annonc/mds643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037425350
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1093/annonc/mdu264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024326332
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1111/bjh.12046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001169896
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1111/j.1365-2141.2006.05970.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034825932
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1111/j.1600-0609.2005.00438.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047241465
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1177/107327481201900307 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078579904
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1182/blood-2007-06-095331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016624678
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1182/blood-2014-03-559930 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007936408
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1182/blood-2014-05-521898 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022647132
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1200/jco.20.5.1288 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064202851
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1200/jco.2005.08.133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012126812
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1200/jco.2005.55.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204326
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.2008.16.8435 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053491476
226 rdf:type schema:CreativeWork
227 https://doi.org/10.3109/10428194.2012.656628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030110268
228 rdf:type schema:CreativeWork
229 https://doi.org/10.3109/10428194.2012.733882 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018029031
230 rdf:type schema:CreativeWork
231 https://www.grid.ac/institutes/grid.482857.4 schema:alternateName BresMed
232 schema:name BresMed, 84 Queen Street, S1 2DW, Sheffield, UK
233 rdf:type schema:Organization
234 https://www.grid.ac/institutes/grid.497524.9 schema:alternateName Janssen (Germany)
235 schema:name Janssen-Cilag, Johnson & Johnson Platz 1, 41470, Neuss, Germany
236 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...